Xiaoliang Hua
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiaoliang Hua has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Chaozhao Liang
Department of Urology the First Affiliated Hospital of Anhui Medical University Hefei China
3 shared publications - Li Zhang
Department of Urology, the First Affiliated Hospital of Anhui Medical University Anhui Medical University Hefei Anhui China
3 shared publications - Jiong Zhang
School of Civil Engineering and Architecture, Wuyi University, Jiangmen, China
2 shared publications - Qing Jiang
Department of Urology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
2 shared publications - Rui Feng
Department of Urology the First Affiliated Hospital of Anhui Medical University Hefei China
2 shared publications - Chang Liu
Department of Urology, The First Affiliated Hospital of Anhui Medical University, Anhui Medical University, Hefei, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (2) , 388-401
Alcohol Intake-Induced Aggravation of Chronic Prostatitis/Chronic Pelvic Pain Syndrome is Associated with Reduced Gut Microbiota-Driven Short-Chain Fatty Acid Propionate and Butyrate
Liu C, et al. World J Mens Health. 2025 Jun;43:e30. https://doi.org/10.5534/wjmh.240223
- 1 January 2026
- Published by XMLink in The World Journal of Men's Health
- Vol. 44 (2) , 388-401
Open AccessAlcohol Intake-Induced Aggravation of Chronic Prostatitis/Chronic Pelvic Pain Syndrome is Associated with Reduced Gut Microbiota-Driven Short-Chain Fatty Acid Propionate and Butyrate
Liu C, et al. World J Mens Health. 2025 Jun;43:e30. https://doi.org/10.5534/wjmh.240223
- 5 March 2024
- Published by Wiley in The Prostate
- Vol. 84 (7) , 666-681
Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway
Background: Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) leads to severe discomfort in males and loss of sperm quality. Current therapeutic options have failed to achieve satisfactory results. Sodium butyrate (NaB) plays a beneficial role in reducing inflammation, increasing antioxidant capacities, and improving organ dysfunction; additionally NaB has good safety prospects and great potential for clinical application. The purpose of the current research was to study the effect of NaB on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice.Methods: The EAP mouse model was successfully established by subcutaneously injecting a mixture of prostate antigen and complete Freund's adjuvant. Then, EAP mice received daily intraperitoneal injections of NaB (100, 200, or 400 mg/kg/day) for 16 days, from Days 26 to 42. We then explored anti‐inflammatory potential mechanisms of NaB by studying the effects of Nrf2 inhibitor ML385 and HO‐1 inhibitor zinc protoporphyrin on prostate inflammation and pelvic pain using this model. On Day 42, hematoxylin‐eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying Von Frey filaments to the lower abdomen. The levels of inflammation‐related cytokines, such as interleukin (IL)−1β, IL‐6, and tumor necrosis factor were detected by enzyme‐linked immunosorbent assay. The regulation of Nrf2/HO‐1 signaling pathway and the expression of NLRP3 inflammasome‐related protein in EAP mice were detected by western blot analysis assay.Results: Compared with the EAP group, chronic pain development, histological manifestations, and cytokine levels showed that NaB reduced the severity of EAP. NaB treatment could inhibit NLRP3 inflammasome activation. Mechanism studies showed that NaB intervention could alleviate oxidative stress in EAP mice through Nrf2/HO‐1 signal pathway. Nrf2/HO‐1 pathway inhibitors can inhibit NaB ‐mediated oxidative stress. The inhibitory effect of NaB on the activation of NLRP3 inflammasome and anti‐inflammatory effect can also be blocked by Nrf2/HO‐1 pathway.Conclusions: NaB treatment can alleviates prostatic inflammation and pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway. NaB has the potential as an effective agent in the treatment of EAP.
- 5 March 2024
- Published by Wiley in The Prostate
- Vol. 84 (7) , 666-681
Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway
Background: Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) leads to severe discomfort in males and loss of sperm quality. Current therapeutic options have failed to achieve satisfactory results. Sodium butyrate (NaB) plays a beneficial role in reducing inflammation, increasing antioxidant capacities, and improving organ dysfunction; additionally NaB has good safety prospects and great potential for clinical application. The purpose of the current research was to study the effect of NaB on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice.Methods: The EAP mouse model was successfully established by subcutaneously injecting a mixture of prostate antigen and complete Freund's adjuvant. Then, EAP mice received daily intraperitoneal injections of NaB (100, 200, or 400 mg/kg/day) for 16 days, from Days 26 to 42. We then explored anti‐inflammatory potential mechanisms of NaB by studying the effects of Nrf2 inhibitor ML385 and HO‐1 inhibitor zinc protoporphyrin on prostate inflammation and pelvic pain using this model. On Day 42, hematoxylin‐eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying Von Frey filaments to the lower abdomen. The levels of inflammation‐related cytokines, such as interleukin (IL)−1β, IL‐6, and tumor necrosis factor were detected by enzyme‐linked immunosorbent assay. The regulation of Nrf2/HO‐1 signaling pathway and the expression of NLRP3 inflammasome‐related protein in EAP mice were detected by western blot analysis assay.Results: Compared with the EAP group, chronic pain development, histological manifestations, and cytokine levels showed that NaB reduced the severity of EAP. NaB treatment could inhibit NLRP3 inflammasome activation. Mechanism studies showed that NaB intervention could alleviate oxidative stress in EAP mice through Nrf2/HO‐1 signal pathway. Nrf2/HO‐1 pathway inhibitors can inhibit NaB ‐mediated oxidative stress. The inhibitory effect of NaB on the activation of NLRP3 inflammasome and anti‐inflammatory effect can also be blocked by Nrf2/HO‐1 pathway.Conclusions: NaB treatment can alleviates prostatic inflammation and pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO‐1 pathway. NaB has the potential as an effective agent in the treatment of EAP.
- Open Access
- 1 August 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 3365-3379
Resolvin D1 Attenuates Inflammation and Pelvic Pain Associated with EAP by Inhibiting Oxidative Stress and NLRP3 Inflammasome Activation via the Nrf2/HO-1 Pathway
Background: Resolvin D1 (RvD1), a member of the specialized pro-resolving lipid mediators family, has a potent anti-inflammatory effect and alleviates tissue damage. The purpose of the current research was to study the effect of RvD1 on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice. Materials and Methods: The EAP mouse model was successfully established, and was used to test the therapeutic effect of RvD1. Hematoxylin-eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying von Frey filaments to the lower abdomen. The superoxide dismutase enzyme and malondialdehyde levels were detected using enzyme-linked immunosorbent assay (ELISA). The levels of inflammation-related cytokines, including IL-1β, IL-6, and TNF-α were detected by ELISA. Results: RvD1 treatment ameliorated prostatic inflammation and the pelvic pain of EAP mice. RvD1 treatment could inhibit activation of the NLRP3 inflammasome and oxidative stress. RvD1 treatment could activate Nrf2/HO-1 signaling in mice with EAP. Blockade of Nrf2/HO-1 signaling abolished the RvD1-mediated inhibition of oxidative stress, NLRP3 inflammasome activation and the anti-inflammatory effect of RvD1 in EAP. Conclusion: RvD1 treatment can reduce inflammatory cell infiltration in prostate tissue and attenuate pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. These results provide new insights that RvD1 has the potential as an effective agent in the treatment of EAP.
- 1 August 2023
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 16, 3365-3379
Open AccessResolvin D1 Attenuates Inflammation and Pelvic Pain Associated with EAP by Inhibiting Oxidative Stress and NLRP3 Inflammasome Activation via the Nrf2/HO-1 Pathway
Background: Resolvin D1 (RvD1), a member of the specialized pro-resolving lipid mediators family, has a potent anti-inflammatory effect and alleviates tissue damage. The purpose of the current research was to study the effect of RvD1 on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice. Materials and Methods: The EAP mouse model was successfully established, and was used to test the therapeutic effect of RvD1. Hematoxylin-eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying von Frey filaments to the lower abdomen. The superoxide dismutase enzyme and malondialdehyde levels were detected using enzyme-linked immunosorbent assay (ELISA). The levels of inflammation-related cytokines, including IL-1β, IL-6, and TNF-α were detected by ELISA. Results: RvD1 treatment ameliorated prostatic inflammation and the pelvic pain of EAP mice. RvD1 treatment could inhibit activation of the NLRP3 inflammasome and oxidative stress. RvD1 treatment could activate Nrf2/HO-1 signaling in mice with EAP. Blockade of Nrf2/HO-1 signaling abolished the RvD1-mediated inhibition of oxidative stress, NLRP3 inflammasome activation and the anti-inflammatory effect of RvD1 in EAP. Conclusion: RvD1 treatment can reduce inflammatory cell infiltration in prostate tissue and attenuate pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. These results provide new insights that RvD1 has the potential as an effective agent in the treatment of EAP.
- Open Access
- 18 September 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-10
A costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma
Costimulatory molecules have been proven to enhance antitumor immune responses, but their roles in clear cell renal cell carcinoma (ccRCC) remain unexplored. In this study, we aimed to explore the gene expression profiles of costimulatory molecule genes in ccRCC and construct a prognostic signature to improve treatment decision-making and clinical outcomes. We performed the first comprehensive analysis of costimulatory molecules in patients with ccRCC and identified 13 costimulatory molecule genes with prognostic values and diagnostic values. Consensus clustering analysis based on these 13 costimulatory molecular genes showed different distribution patterns and prognostic differences for the two clusters identified. Then, a costimulatory molecule-related signature was constructed based on these 13 costimulatory molecular genes, and validated in an external dataset, showing good performance for predicting a patient’s prognosis. The signature was an independent risk factor for ccRCC patients and was significantly correlated with patients’ clinical factors, which could be used as a complement for clinical factors. In addition, the signature was associated with the tumor immune microenvironment and the response to immunotherapy. Patients identified as high-risk based on our signature exhibited a high mutation frequency, a high level of immune cell infiltration, and an immunosuppressive microenvironment. High-risk patients tended to have high cytolytic activity scores and immunophenoscore of CTLA4 and PD1/PD-L1/PD-L2 blocker than low-risk patients, suggesting these patients may be more suitable for immunotherapy. Therefore, our signature could provide clinicians with prognosis predictions and help guide treatment for ccRCC patients.
- 18 September 2021
- Published by Springer Nature in Cell Death Discovery
- Vol. 7 (1) , 1-10
Open AccessA costimulatory molecule-related signature in regard to evaluation of prognosis and immune features for clear cell renal cell carcinoma
Costimulatory molecules have been proven to enhance antitumor immune responses, but their roles in clear cell renal cell carcinoma (ccRCC) remain unexplored. In this study, we aimed to explore the gene expression profiles of costimulatory molecule genes in ccRCC and construct a prognostic signature to improve treatment decision-making and clinical outcomes. We performed the first comprehensive analysis of costimulatory molecules in patients with ccRCC and identified 13 costimulatory molecule genes with prognostic values and diagnostic values. Consensus clustering analysis based on these 13 costimulatory molecular genes showed different distribution patterns and prognostic differences for the two clusters identified. Then, a costimulatory molecule-related signature was constructed based on these 13 costimulatory molecular genes, and validated in an external dataset, showing good performance for predicting a patient’s prognosis. The signature was an independent risk factor for ccRCC patients and was significantly correlated with patients’ clinical factors, which could be used as a complement for clinical factors. In addition, the signature was associated with the tumor immune microenvironment and the response to immunotherapy. Patients identified as high-risk based on our signature exhibited a high mutation frequency, a high level of immune cell infiltration, and an immunosuppressive microenvironment. High-risk patients tended to have high cytolytic activity scores and immunophenoscore of CTLA4 and PD1/PD-L1/PD-L2 blocker than low-risk patients, suggesting these patients may be more suitable for immunotherapy. Therefore, our signature could provide clinicians with prognosis predictions and help guide treatment for ccRCC patients.